JPH09124488A - Epidermal keratinization-promoting agent - Google Patents

Epidermal keratinization-promoting agent

Info

Publication number
JPH09124488A
JPH09124488A JP30990395A JP30990395A JPH09124488A JP H09124488 A JPH09124488 A JP H09124488A JP 30990395 A JP30990395 A JP 30990395A JP 30990395 A JP30990395 A JP 30990395A JP H09124488 A JPH09124488 A JP H09124488A
Authority
JP
Japan
Prior art keywords
ethyl
dandruff
test
skin
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP30990395A
Other languages
Japanese (ja)
Other versions
JP3534921B2 (en
Inventor
Nobuo Kitamura
伸夫 北村
Yukiko Oota
裕紀子 太田
Osamu Tanno
修 丹野
Akinori Haratake
昭憲 原武
Toshio Horikoshi
俊男 堀越
Takeshi Ikemoto
毅 池本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanebo Ltd
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Priority to JP30990395A priority Critical patent/JP3534921B2/en
Publication of JPH09124488A publication Critical patent/JPH09124488A/en
Application granted granted Critical
Publication of JP3534921B2 publication Critical patent/JP3534921B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To obtain an epidermal keratinization-promoting agent effective for the improvement of dermal diseases such as an atopic dermatitis, psoriasis, xeroderma, symptomatic dandruff in head skin and further roughness in lip. SOLUTION: This epidermal keratinization promoting agent contains an α-ethylglycoside. As the α-ethylglycoside used, α-ethylglucose (ethyl α-D- glucopyranoside), α-ethylgalactose, α-ethylmannose, α-ethylallose, α-ethylaltrose, α-ethylgulose, α-ethyltalose, α-ethylxylose, α-ethylarabinose, α-ethylmaltose and α-ethylcellobiose are cited.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は、皮膚表皮層内部で
表皮細胞の角質化を促進し、皮膚バリアー機能を改善す
ることにより、アトピー性皮膚炎、乾癬を始め、乾皮症
や頭皮のフケ症、さらに口唇の荒れなど各種皮膚疾患の
改善に有効な表皮角質化促進剤に関する。
TECHNICAL FIELD The present invention relates to the promotion of keratinization of epidermal cells inside the skin epidermal layer and improvement of the skin barrier function, thereby causing atopic dermatitis, psoriasis, psoriasis and dandruff of the scalp. The present invention relates to an agent for promoting keratinization of the epidermis, which is effective for alleviating various skin diseases such as dermatosis and rough lip.

【0002】[0002]

【従来の技術】皮膚表皮における角質層は、皮膚の保湿
能や生体の物理的保護を始めとする一連の生理的役割を
演じており、生命活動において重要な役割をになってい
る。しかし、いわゆるアトピー性皮膚炎、乾癬を始め、
乾皮症や頭皮のフケ症、さらに口唇の荒れなどの皮膚疾
患では、健全な角質層の形成が妨げられていることが多
い。
BACKGROUND OF THE INVENTION The stratum corneum in the epidermis of the skin plays a series of physiological roles such as moisturizing ability of the skin and physical protection of the living body, and plays an important role in life activities. However, including so-called atopic dermatitis and psoriasis,
Skin diseases such as xeroderma, dandruff on the scalp, and rough lips often prevent the formation of a healthy stratum corneum.

【0003】皮膚表面の角質層の不全は、皮膚バリアー
機能の低下をもたらし、外界からの異物の浸入及び水分
等の体内物質の蒸散が容易になる結果、各種皮膚疾患の
惹起あるいは悪化に結び付くと考えられる。
Insufficiency of the stratum corneum on the surface of the skin leads to deterioration of the skin barrier function, facilitating the infiltration of foreign substances from the outside and the evaporation of body substances such as water, resulting in the initiation or deterioration of various skin diseases. Conceivable.

【0004】このような皮膚疾患を防止し、健常な皮膚
を維持するために、ある種の成分を投与することにより
皮膚のトラブルを正常化することが考えられる。従来、
上記目的のための主たる方法として、保湿成分を投与す
ることで皮膚の乾燥状態を防ぎ潤いを持たせることが行
われてきた。
[0004] In order to prevent such skin diseases and maintain healthy skin, it is conceivable to normalize skin troubles by administering certain components. Conventionally,
As a main method for the above purpose, it has been practiced to prevent the skin from drying out and give it moisture by administering a moisturizing component.

【0005】しかし、前記従来の方法は、一般的に角質
表面の水分補給あるいは保湿成分の一部補給を行うもの
であり、その効果が一時的なものに留まり、皮膚バリア
ー機能の回復効果を持続的に与える事ができない(武村
俊之:ファルマシア、28、1、1992)。したがっ
て、持続的に皮膚バリアー機能を回復させる方法が望ま
れていた。
However, the above-mentioned conventional method generally replenishes water on the surface of the corneum or partially replenishes the moisturizing component, and the effect is only temporary, and the recovery effect of the skin barrier function is maintained. Cannot be given (Toshiyuki Takemura: Pharmacia, 28, 1, 1992). Therefore, a method for continuously recovering the skin barrier function has been desired.

【0006】[0006]

【発明が解決しようとする課題】従って、本発明の目的
とするところは、アトピー性皮膚炎、乾癬を始め、乾皮
症や頭皮のフケ症、さらに口唇の荒れなどの皮膚疾患の
改善に有効な表皮角質化促進剤を提供するにある。
Therefore, the object of the present invention is to improve skin diseases such as atopic dermatitis, psoriasis, psoriasis, scalp dandruff, and rough lip. To provide a keratinization promoting agent for epidermis.

【0007】[0007]

【課題を解決するための手段】かかる事情に鑑み、本発
明者等は、表皮細胞自身の角質化を促進させる事を意図
し、培養表皮細胞での探索を鋭意検討してきた結果、α
−エチルグリコシドが促進作用を有することを見出し、
本発明を完成するに至った。
In view of the above circumstances, the present inventors have diligently investigated the search for cultured epidermal cells with the intention of promoting keratinization of the epidermal cells themselves, and as a result, α
-Finding that ethyl glycoside has a promoting action,
The present invention has been completed.

【0008】即ち、本発明はα−エチルグリコシドを含
有する角質化促進剤に関するものである。
That is, the present invention relates to a keratinization promoting agent containing α-ethyl glycoside.

【0009】[0009]

【発明の実施の形態】以下、本発明の構成について詳説
する。
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The configuration of the present invention will be described below in detail.

【0010】本発明に用いられるα−エチルグリコシド
としては、α−エチルグルコース(ethyl α-D-glucopy
ranoside)、α−エチルガラクトース、α−エチルマン
ノース、α−エチルアロース、α−エチルアルトロー
ス、α−エチルグロース、α−エチルタロース、α−エ
チルキシロース、α−エチルアラビノース、α−エチル
マルトース、α−エチルセルビオース等が挙げられ、中
でも特にα−エチルグルコース、α−エチルマルトース
が好ましい。これらは合成されたものまたは天然から抽
出されたもののいずれでも良く、例えば、文献 'Roczni
k Chemi., 第49巻、第12号、第2113〜2115頁、1975年等
に記載の合成方法によって得ることができる。
The α-ethyl glycoside used in the present invention includes α-ethyl glucose (ethyl α-D-glucopy).
ranoside), α-ethylgalactose, α-ethylmannose, α-ethylallose, α-ethylaltrose, α-ethylgulose, α-ethyltalose, α-ethylxylose, α-ethylarabinose, α-ethylmaltose, α- Examples thereof include ethyl cellobiose, and among them, α-ethyl glucose and α-ethyl maltose are particularly preferable. These may be either synthetic or extracted from nature, see for example the literature 'Roczni.
k Chemi., Vol. 49, No. 12, pages 2113 to 2115, 1975, etc.

【0011】本発明の表皮角質化促進剤の組成物形態と
しては、特に制限されないが、例えば、溶液、軟膏、ロ
ーション、パウダー、乳液、シャンプー等の皮膚外用剤
が挙げられる。また、該皮膚外用剤には、公知の外用基
剤を適宜用いることができる。
The composition form of the epidermal keratinization promoting agent of the present invention is not particularly limited, but examples thereof include external preparations for skin such as solutions, ointments, lotions, powders, emulsions and shampoos. Further, as the external preparation for skin, a known external base can be appropriately used.

【0012】本発明の表皮角質化促進剤中のα−エチル
グリコシドの配合量としては、組成物総量を基準として
全組成量の0.001〜5重量%が好ましい。
The blending amount of α-ethyl glycoside in the epidermal keratinization promoting agent of the present invention is preferably 0.001 to 5% by weight based on the total amount of the composition.

【0013】[0013]

【実施例】以下、実施例により本発明を更に詳細に説明
する。実施例に先立ち、角質化促進試験、動物モデル肌
荒れ抑制試験、フケ抑制試験、口唇荒れ試験について述
べる。
The present invention will be described in more detail with reference to the following examples. Prior to the examples, a keratinization promotion test, an animal model skin roughness suppression test, an dandruff suppression test, and a lip roughness test will be described.

【0014】試験例1(角質化促進試験) (1)試験方法 (a)培養表皮細胞 ヒト正常表皮細胞は市販品(Cascade Biology 社製)を
用いた。
Test Example 1 (Keratinization promotion test) (1) Test method (a) Cultured epidermal cells Commercially available human normal epidermal cells (manufactured by Cascade Biology) were used.

【0015】(b)細胞培養用培地 培地としては、MCDB153HAA培地(極東社製)
をベースにして、これにハイドロコーチゾン(0.5μ
M)、エタノールアミン(0.1mM)、ホスホエタノ
ールアミン(0.1mM)、インシュリン(5μg/m
l)、およびEGF(上皮細胞成長因子:10ng/m
l)を加えたK−GM培地を用いた。又細胞の増殖培養
時には、これにBPE(牛脳下垂体抽出液)(Cascade
Biology社製)を添加して(4μl/ml培地)用い
た。
(B) Cell Culture Medium As the medium, MCDB153HAA medium (manufactured by Kyokuto)
On the basis of this, hydrocortisone (0.5μ
M), ethanolamine (0.1 mM), phosphoethanolamine (0.1 mM), insulin (5 μg / m
l) and EGF (epidermal growth factor: 10 ng / m
The K-GM medium to which 1) was added was used. In addition, during cell culture, BPE (bovine pituitary extract) (Cascade
Biology) was added (4 μl / ml medium) and used.

【0016】(c)Hepes緩衝液の調製 Hepes7.15g 、グルコース1.8g 、塩化カリ
ウム0.22g 、塩化ナトリウム7.7g 、リン酸水素
二ナトリウム・12水和物0.27g を精製水に溶解
し、1N水酸化ナトリウム水溶液にてpH7.4に調製
後、1lにメスアップした。
(C) Preparation of Hepes buffer Hepes 7.15 g, glucose 1.8 g, potassium chloride 0.22 g, sodium chloride 7.7 g, and disodium hydrogen phosphate dodecahydrate 0.27 g were dissolved in purified water. Then, the pH was adjusted to 7.4 with a 1N aqueous sodium hydroxide solution, and the volume was adjusted to 1 l.

【0017】(d)細胞培養 正常ヒト表皮細胞の細胞数をK−GM培地(BPE添
加)にて1×104 個/mlに調製し、24穴コラーゲ
ンコートプレート(コーニング社製)に1mlずつ播種
し、95%空気(V/V)−5%炭酸ガス(V/V)の
雰囲気下、37℃で4日間静置培養した。その後、3、
10、30μg/mlの各α−エチルグルコースおよび
比較として30μg/mlのβ−エチルグルコースを添
加したK−GM培地(BPE添加:0.4μl/ml培
地)に交換して、95%空気(V/V)−5%炭酸ガス
(V/V)の雰囲気下、37℃で7日間静置培養した。
この間2日置きに培地交換を行った。
(D) Cell Culture The number of normal human epidermal cells was adjusted to 1 × 10 4 cells / ml in K-GM medium (BPE added), and 1 ml each was placed on a 24-well collagen-coated plate (manufactured by Corning). The seeds were seeded and statically cultured at 37 ° C. for 4 days in an atmosphere of 95% air (V / V) -5% carbon dioxide (V / V). After that, 3,
The medium was replaced with K-GM medium (BPE addition: 0.4 μl / ml medium) supplemented with 10, 30 μg / ml each α-ethyl glucose and 30 μg / ml β-ethyl glucose for comparison, and 95% air (V / V) -5% carbon dioxide (V / V) atmosphere, static culture was carried out at 37 ° C for 7 days.
During this period, the medium was replaced every two days.

【0018】(f)角質膜形成能の測定 培養後、培養上清を吸引除去し、Hepes緩衝液で2
回洗浄した後、細胞をトリプシン処理で剥離させて各穴
の細胞数を血球計算盤で計測した。細胞数計測後、残り
の細胞を20μg/mlのカルシウムイオノフォア(A
23187)および1.25mMカルシウムイオンを含
む500μlの培地にて37℃/2時間静置し、更に1
%SDS(ラウリル硫酸ナトリウム)/20mM DT
T(ジチオスレイトール)液に細胞を溶解し、100℃
5分間熱処理をした。熱処理後、不溶化細胞数を計測
し、処理前の細胞数との比から角質化率を求めた。各添
加薬剤の効果の評価は、コントロールである無添加時の
角質化率を1とした各角質化率の比によって行った。
(F) Measurement of Corneal Membrane Forming Ability After the culture, the culture supernatant is removed by suction, and the cells are washed with Hepes buffer to 2
After washing twice, the cells were detached by trypsin treatment and the number of cells in each well was counted with a hemocytometer. After counting the number of cells, the remaining cells were treated with 20 μg / ml calcium ionophore (A
23187) and 1.25 mM calcium ion in 500 μl of the medium, and allowed to stand at 37 ° C. for 2 hours.
% SDS (sodium lauryl sulfate) / 20 mM DT
Lyse cells in T (dithiothreitol) solution and
Heat treatment was performed for 5 minutes. After the heat treatment, the number of insolubilized cells was counted, and the keratinization rate was calculated from the ratio with the number of cells before treatment. The effect of each added drug was evaluated by the ratio of each keratinization rate, where the keratinization rate in the case of no addition as a control was 1.

【0019】(2)結果 薬剤無添加のコントロール値に比べ、α−エチルグルコ
ース添加培養では表皮細胞の角質化率上昇が見られた
(図1)。これに対しβ−エチルグルコースではほとん
ど角質化率の上昇が認められず、角質化が促進されない
ことが分かった。従って、エチルグルコースはα体に、
特異的にヒト表皮細胞自体の角質化を促進する作用があ
ることが分かった。
(2) Results An increase in the keratinization rate of epidermal cells was observed in the α-ethyl glucose-added culture as compared with the control value without addition of the drug (FIG. 1). On the other hand, with β-ethyl glucose, almost no increase in the keratinization rate was observed, and it was found that keratinization was not promoted. Therefore, ethyl glucose is in α form,
It was found that it has an action of specifically promoting keratinization of human epidermal cells themselves.

【0020】試験例2 (肌荒れ抑制試験) (1)試験方法 UV照射により誘発されるマウス肌荒れモデルを用い、
α−エチルグルコースおよび比較としてβ−エチルグル
コースの肌荒れに対する予防・改善効果を調べた。
Test Example 2 (Rough skin suppression test) (1) Test method Using a mouse rough skin model induced by UV irradiation,
The preventive / ameliorating effects of α-ethyl glucose and β-ethyl glucose as a comparison against rough skin were examined.

【0021】供試動物としてヘアレスマウス(hrー1
系の雄)を購入し、9週齢まで飼育した後、1群5匹で
実験を開始した。
Hairless mice (hr-1) were used as test animals.
(Male of the strain) was purchased and bred until the age of 9 weeks, and the experiment was started with 5 animals per group.

【0022】肌荒れモデルの作成方法としては、ヘアレ
スマウスの後背部に、照射エネルギー0.15J/cm
2 (SEランプ:東芝製)でUV−Bを1回照射する方
法を用いた。
As a method for creating a rough skin model, irradiation energy of 0.15 J / cm was applied to the back of the hairless mouse.
2 (SE lamp: manufactured by Toshiba) was used to irradiate UV-B once.

【0023】肌荒れ抑制効果の検討に当たっては、0.
5%−Triton X150(和光純薬社製)に溶解した0.
01重量%、0.05重量%濃度のα−エチルグルコー
ス又は0.05重量%のβ−エチルグルコースを、それ
ぞれのヘアレスマウス群に一日一回、UV−B照射前5
日間塗布した。UV−B照射後も照射直後から3日間ま
で、照射前塗布と同様各群に一日一回の塗布を行った。
またこの時コントロール群として、エタノールのみを照
射前、照射後に塗布したものを置いた。
In examining the effect of suppressing skin roughness, 0.
0.1% dissolved in 5% -Triton X150 (manufactured by Wako Pure Chemical Industries, Ltd.)
Α-ethyl glucose at a concentration of 01% by weight and 0.05% by weight or β-ethyl glucose at a concentration of 0.05% by weight was applied to each hairless mouse group once a day before UV-B irradiation.
It was applied for a day. Even after UV-B irradiation, each group was applied once a day from immediately after irradiation to 3 days in the same manner as before irradiation.
Further, at this time, as a control group, those coated only with ethanol before and after irradiation were placed.

【0024】経表皮水分喪失量(TEWL)の測定はA
MU−3(フォーション社製)を用いて行い、水分蒸散
量(mg /cm2 /min)で示した。また測定時期は、塗布開
始直前及び開始後3日目に設定した。
The transepidermal water loss (TEWL) was measured by A
MU-3 (manufactured by Forsion Co., Ltd.) was used, and the amount of water transpiration (mg / cm 2 / min) was shown. The measurement time was set just before the start of application and on the third day after the start of application.

【0025】(2)結果 ヘアレスマウス背部へのUV−B照射により、コントロ
ール群は照射後から3日間で開始前の7倍程TEWLの
上昇が見られたが、α−エチルグルコース塗布群は塗布
濃度に相関してTEWLの上昇抑制が見られた。一方β
−エチルグルコースには抑制がみられなかった。(図
2)このことは、α−エチルグルコースがUV−B照射
による肌荒れの惹起を抑制し、肌荒れの改善、予防効果
を示したと言える。
(2) Results By UV-B irradiation of the back of the hairless mouse, the control group showed a 7-fold increase in TEWL 3 days after irradiation, which was 7 times higher than that before the start. An increase in TEWL was suppressed in correlation with the concentration. On the other hand, β
-Ethyl glucose was not suppressed. (FIG. 2) This means that α-ethyl glucose suppressed the induction of skin roughness due to UV-B irradiation, and showed the effect of improving and preventing skin roughness.

【0026】試験例3(フケ抑制試験) (1)試験方法 (a)フケの採取方法 濾布上で被験者の洗髪を行った後、濾布をイオン交換水
の入った5lビーカ内で超音波処理、ついで攪拌するこ
とにより濾布上に残留したフケをビーカ内のイオン交換
水中へ回収した。ビーカ内に混入した毛髪を除去した
後、フケが浮遊したイオン交換水をメンブランフィルタ
ー(ミリポア社製、0.45μm)上で吸引ろ過するこ
とによりフケを回収した。メンブランフィルターを10
mlのイオン交換水でリンスすることによりフィルター
上のフケを回収した。これをフケ試料とした。
Test Example 3 (dandruff suppression test) (1) Test method (a) Method for collecting dandruff After subject's hair was washed on a filter cloth, the filter cloth was ultrasonicated in a 5 l beaker containing ion-exchanged water. The dandruff remaining on the filter cloth was recovered in the ion-exchanged water in the beaker by treating and then stirring. After the hair mixed in the beaker was removed, the dandruff was collected by suction filtration of the ion-exchanged water in which the dandruff floated on a membrane filter (Millipore, 0.45 μm). 10 membrane filters
The dandruff on the filter was collected by rinsing with ml of ion-exchanged water. This was used as an dandruff sample.

【0027】(b)フケ量の測定 フケ試料をゲンチアナバイオレット・ブリリアントグリ
ーンで染色し、光学顕微鏡下で血球計算板を用いて有核
細胞数と無核細胞数をカウントした。フケ総量はフケ試
料10mlの有核細胞数と無核細胞数の合計とした。有
核細胞率は、フケ総量に対する有核細胞数の割合で示し
た。
(B) Measurement of dandruff amount The dandruff sample was stained with gentian violet brilliant green, and the number of nucleated cells and the number of non-nucleated cells were counted using a hemocytometer under an optical microscope. The total amount of dandruff was the total of the number of nucleated cells and the number of non-nucleated cells in 10 ml of dandruff sample. The nucleated cell rate was shown by the ratio of the number of nucleated cells to the total amount of dandruff.

【0028】(c)試験試料の調製 最終濃度が0.05重量%になるように、α−エチルグ
ルコースまたはβ−エチルグルコースを配合した10%
エタノール水溶液を作製し、これらを試験試料とした。
対照試料としてα−エチルグルコース及びβ−エチルグ
ルコース未配合の10%エタノール水溶液を用いた。
(C) Preparation of test sample 10% prepared by blending α-ethyl glucose or β-ethyl glucose to a final concentration of 0.05% by weight.
An aqueous ethanol solution was prepared and used as test samples.
As a control sample, 10% aqueous ethanol solution containing no α-ethyl glucose and β-ethyl glucose was used.

【0029】(d)フケ抑制試験 被験者を3グループに分け(各グループ5名)、試験開
始1日目の朝に被験者のフケを回収し、有核細胞数と無
核細胞数をカウントし、有核細胞率およびフケ総量を算
出した。その後、40日間、被験者には通常のシャンプ
ー、リンスを用いて毎日洗髪をさせ、毎洗髪後に適量の
試験試料(グループ1およびグループ2)および対照試
料(グループ3)を頭皮に外用塗布した。40日後の朝
に被験者のフケを回収し、有核細胞数と無核細胞数をカ
ウントし、有核細胞率およびフケ総量を算出した。
(D) Dandruff suppression test The subjects were divided into 3 groups (5 persons in each group), the dandruff of the subjects was collected on the morning of the first day of the test, and the number of nucleated cells and the number of non-nucleated cells were counted. The nucleated cell rate and the total amount of dandruff were calculated. Thereafter, for 40 days, the subject was washed with normal shampoo and rinse every day, and after each hair wash, an appropriate amount of test sample (group 1 and group 2) and control sample (group 3) were externally applied to the scalp. The dandruff of the subject was collected in the morning 40 days later, the number of nucleated cells and the number of non-nucleated cells were counted, and the nucleated cell ratio and the total amount of dandruff were calculated.

【0030】(2)結果 試験開始1日目のフケ総量に対する40日後のフケ総量
の相対値は、対照試料を投与したグループ3では95
%、α−エチルグルコース配合試料を投与したグループ
1では65%、β−エチルグルコース配合試料を投与し
たグループ2では90%であった。また、グループ2お
よび3の40日後の有核細胞率は、試験開始1日目と同
じであったが、グループ1では有核細胞率の顕著な減少
がみられた。
(2) Results The relative value of the total amount of dandruff 40 days after the first day of the test was 95 in the group 3 to which the control sample was administered.
%, 65% in group 1 administered with the α-ethyl glucose combination sample, and 90% in group 2 administered with the β-ethyl glucose combination sample. In addition, the nucleated cell rate after 40 days in groups 2 and 3 was the same as that on the first day from the start of the test, but in group 1, a marked decrease in the nucleated cell rate was observed.

【0031】また、実施例4と5に記載のα−エチルグ
ルコースを1重量%配合したシャンプーおよびリンスを
作製し、被験者5名に使用させたところ、試験開始1日
目のフケ総量に比べ、40日後のフケ総量が60%に減
少した。これらの結果から、α−エチルグルコースには
フケ抑制作用があることが明らかとなった。
Further, shampoos and rinses containing 1% by weight of α-ethyl glucose described in Examples 4 and 5 were prepared and used by 5 test subjects, and compared with the total amount of dandruff on the first day of the test, After 40 days, the total amount of dandruff decreased to 60%. From these results, it was revealed that α-ethyl glucose has an antidandruff effect.

【0032】試験例4(口唇荒れ改善試験) (1)試験方法 (a)口唇荒れの判定 自覚症状および有核細胞数により判定した。自覚症状と
して皮むけがおきる、カサつく、の両者を持つ被験者を
グループA(15名)、両者の自覚のないものをグルー
プB(5名)とした。有核細胞数は細胞摂取板(鐘紡
製、粘着部面積7mm直径)で下唇中央部より角質細胞
を剥離した。細胞の付着した細胞摂取板はゲンチアナバ
イオレット・ブリリアントグリーンで染色し、光学顕微
鏡下で4mm2 内の有核細胞数を3ケ所カウントし、そ
の平均を有核細胞数とした。
Test Example 4 (Rough Lip Improvement Test) (1) Test Method (a) Judgment of Rough Lip Judgment was made based on subjective symptoms and the number of nucleated cells. Subjects having both skin peeling and dryness as subjective symptoms were designated as group A (15 persons), and subjects not having both subjective symptoms were designated as group B (5 persons). For the number of nucleated cells, keratinocytes were detached from the central part of the lower lip using a cell uptake plate (made by Kanebo, adhesive area 7 mm diameter). The cell uptake plate with the cells attached thereto was stained with gentian violet brilliant green, and the number of nucleated cells within 4 mm 2 was counted at 3 places under an optical microscope, and the average was taken as the number of nucleated cells.

【0033】(b)試験液の調製 最終濃度が0.1重量%になるように、α−エチルグル
コースまたはβ−エチルグルコースを溶解した水溶液を
作製し、これらを試験試料とした。対照試料として水を
用いた。
(B) Preparation of test solution An aqueous solution in which α-ethyl glucose or β-ethyl glucose was dissolved was prepared so that the final concentration was 0.1% by weight, and these were used as test samples. Water was used as a control sample.

【0034】(c)口唇荒れ改善試験 グループAおよびグループBの有核細胞数は、それぞれ
13.7±3.3、3.7±2.4(Cells/4mm2)であ
った。グループAを5名ずつ3つにわけ、グループA-
1、グループA-2、グループA-3とした。グループA-1
にはα−エチルグルコース配合試料を、グループA-2に
はβ−エチルグルコース配合試料を、また、グループA
-3には対照試料を1日2回、40日間、唇に塗布した。
(C) Lip Roughness Improvement Test The numbers of nucleated cells in Group A and Group B were 13.7 ± 3.3 and 3.7 ± 2.4 (Cells / 4 mm 2 ), respectively. Group A is divided into 3 groups of 5 people each.
1, group A-2 and group A-3. Group A-1
Α-Ethylglucose combination sample for Group A-2, β-Ethylglucose combination sample for Group A-2, and Group A
For -3, a control sample was applied to the lips twice a day for 40 days.

【0035】(2)結果 40日後の有核細胞数はα−エチルグルコース配合水溶
液を塗布したグループA-1のみが、試験前の有核細胞数
に比べ顕著に低下した。また、グループA-1にのみ自覚
症状の改善が認められた。このことから、α−エチルグ
ルコースは口唇荒れ改善効果を有していることが明らか
となった。また、実施例6に記載のα−エチルグルコー
ス配合リップクリームを用いた場合も、同様の効果が確
認された。
(2) Results The number of nucleated cells after 40 days was remarkably reduced in only the group A-1 coated with the α-ethyl glucose-containing aqueous solution, as compared with the number of nucleated cells before the test. Further, improvement of subjective symptoms was observed only in group A-1. From this, it became clear that α-ethyl glucose has a rough lip improving effect. Also, when the α-ethyl glucose-containing lip balm described in Example 6 was used, the same effect was confirmed.

【0036】実施例1 蒸留水100mlにα−エチルグルコース(東京化成社
より購入)0.5gを溶解し、濾過穴径0.22μmの
膜(ミリポア社製)で濾過してα−エチルグルコース水
溶液を得た。
Example 1 0.5 g of α-ethyl glucose (purchased from Tokyo Kasei Co., Ltd.) was dissolved in 100 ml of distilled water, filtered through a membrane (manufactured by Millipore) having a pore size of 0.22 μm, and an aqueous α-ethyl glucose solution was obtained. Got

【0037】実施例2 下記親水性成分を湯浴で80℃に加温し、混合した下記
親油性成分に攪拌しながら徐々に加えた。次に、ホモゲ
ナイザーで攪拌して、各成分を充分乳化分散させた後、
攪拌しながら徐々に冷却し、α−エチルグルコースの軟
膏を得た。
Example 2 The following hydrophilic component was heated to 80 ° C. in a water bath and gradually added to the mixed lipophilic component described below with stirring. Next, after stirring with a homogenizer to sufficiently emulsify and disperse each component,
The mixture was gradually cooled with stirring to obtain an α-ethyl glucose ointment.

【0038】 「親水性成分」 パラオキシ安息香酸メチル 0.1g プロピレングリコール 6.7g 実施例1の水溶液 44.1g“Hydrophilic component” Methyl paraoxybenzoate 0.1 g Propylene glycol 6.7 g Aqueous solution of Example 1 44.1 g

【0039】 「親油性成分」 スクワラン 4.7g 白色ワセリン 24.0g ステアリルアルコール 8.7g ミリスチル酸イソプロピル 6.0g モノステアリン酸イソプロピル 1.3g ポリオキシエチレンアルキルエーテルリン酸 2.3g モノステアリン酸グリセリン 2.0g パラオキシ安息香酸ブチル 0.1g “Lipophilic component” Squalane 4.7 g White petrolatum 24.0 g Stearyl alcohol 8.7 g Isopropyl myristate 6.0 g Isopropyl monostearate 1.3 g Polyoxyethylene alkyl ether phosphate 2.3 g Glycerin monostearate 2 0.0 g Butyl paraoxybenzoate 0.1 g

【0040】実施例3 実施例1で得た水溶液1mlを以下の組成物に加え、α−
エチルグルコース配合のローション100gを得た。
Example 3 1 ml of the aqueous solution obtained in Example 1 was added to the following composition, and α-
100 g of lotion containing ethyl glucose was obtained.

【0041】 エタノール 10.0g 乳酸 0.3g クエン酸ナトリウム 0.1g グリセリン 2.0g 防腐剤、香料及び界面活性剤 適量 精製水 残量Ethanol 10.0 g Lactic acid 0.3 g Sodium citrate 0.1 g Glycerin 2.0 g Preservative, fragrance and surfactant Suitable amount Purified water Remaining amount

【0042】実施例4 以下に示すα−エチルグルコース配合のシャンプー10
0gを得た。
Example 4 Shampoo 10 containing α-ethyl glucose as shown below
0 g was obtained.

【0043】 α−エチルグルコース 1.0g ラウリルポリオキシエチレン(3)硫酸 エステルナトリウム塩(30%水溶液) 30.0g ラウリル硫酸エステルナトリウム塩 (30%水溶液) 10.0g ヤシ油脂肪酸ジエタノールアミド 0.3g グリセリン 0.1g 防腐剤、香料、キレート剤、pH調整剤及び色素 適量 精製水 残量Α-Ethyl glucose 1.0 g Lauryl polyoxyethylene (3) sulfate sodium salt (30% aqueous solution) 30.0 g Lauryl sulfate sodium salt (30% aqueous solution) 10.0 g Coconut oil fatty acid diethanolamide 0.3 g Glycerin 0.1g Preservatives, fragrances, chelating agents, pH adjusters and pigments Appropriate amount Purified water Remaining amount

【0044】実施例5 以下に示す、α−エチルグルコース配合のリンスを10
0g得た。
Example 5 The following rinse with α-ethyl glucose was used.
0 g was obtained.

【0045】 α−エチルグルコース 1.0g 流動パラフィン 1.0g ステアリルアルコール 2.5g 塩化ステアリルトリメチルアンモニウム 1.0g グリセリン 3.0g 防腐剤、香料及び色素 適量 精製水 残量Α-Ethylglucose 1.0 g Liquid paraffin 1.0 g Stearyl alcohol 2.5 g Stearyltrimethylammonium chloride 1.0 g Glycerin 3.0 g Preservatives, perfumes and dyes Appropriate amount Purified water Remaining amount

【0046】実施例6 以下に示す、α−エチルグルコース配合のリップクリー
ムを100g得た。
Example 6 100 g of α-ethyl glucose-containing lip cream shown below was obtained.

【0047】 α−エチルグルコース 1.0g パラフィン 40.0g 流動パラフィン 26.0g ミリスチン酸イソプロピル 10.0g ラノリン 23.0g 香料及び酸化防止剤 適量Α-Ethyl glucose 1.0 g Paraffin 40.0 g Liquid paraffin 26.0 g Isopropyl myristate 10.0 g Lanolin 23.0 g Perfume and antioxidant Suitable amount

【0048】[0048]

【発明の効果】以上の如く、本発明により、皮膚表皮層
内部で表皮細胞の角質化を促進し、皮膚バリアー機能を
改善することにより、アトピー性皮膚炎、乾癬を始め、
乾皮症や頭皮のフケ症、さらに口唇の荒れなどの皮膚疾
患の改善に有効な表皮角質化促進剤を提供できることは
明らかである。
As described above, according to the present invention, keratinization of epidermal cells within the skin epidermis layer is promoted, and the skin barrier function is improved, thereby starting atopic dermatitis and psoriasis.
It is clear that an agent for promoting keratinization of the epidermis can be provided, which is effective in improving skin diseases such as xeroderma, scalp dandruff, and rough lip.

【図面の簡単な説明】[Brief description of the drawings]

【図1】試験例1におけるα−エチルグルコースの効果
を示す図である。
FIG. 1 is a diagram showing the effect of α-ethyl glucose in Test Example 1.

【図2】試験例2における表皮細胞のセラミド産生に及
ぼすα−エチルグルコースの効果を示す図である。
FIG. 2 is a graph showing the effect of α-ethyl glucose on ceramide production by epidermal cells in Test Example 2.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 原武 昭憲 神奈川県小田原市寿町5丁目3番28号 鐘 紡株式会社化粧品研究所内 (72)発明者 堀越 俊男 神奈川県小田原市寿町5丁目3番28号 鐘 紡株式会社化粧品研究所内 (72)発明者 池本 毅 神奈川県小田原市寿町5丁目3番28号 鐘 紡株式会社化粧品研究所内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Akinori Hara, 5-3 28, Kotobuki-cho, Odawara-shi, Kanagawa, Kanebo Co., Ltd. (72) Inventor Toshio Horikoshi 5-chome, 3-cho, Odawara, Kanagawa No. 28 Kanebo Co., Ltd. Cosmetic Research Institute (72) Inventor Takeshi Ikemoto 5-3 28, Kotobuki-cho, Odawara-shi, Kanagawa Kanebo Co., Ltd. Cosmetic Research Institute

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 α−エチルグリコシドを含有することを
特徴とする表皮角質化促進剤。
1. An epidermal keratinization promoting agent, which comprises α-ethyl glycoside.
【請求項2】 α−エチルグリコシドが、α−エチルグ
ルコースである請求項1記載の表皮角質化促進剤。
2. The epidermal keratinization promoting agent according to claim 1, wherein the α-ethyl glycoside is α-ethyl glucose.
JP30990395A 1995-11-02 1995-11-02 Epidermal keratinization promoter Expired - Fee Related JP3534921B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP30990395A JP3534921B2 (en) 1995-11-02 1995-11-02 Epidermal keratinization promoter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP30990395A JP3534921B2 (en) 1995-11-02 1995-11-02 Epidermal keratinization promoter

Publications (2)

Publication Number Publication Date
JPH09124488A true JPH09124488A (en) 1997-05-13
JP3534921B2 JP3534921B2 (en) 2004-06-07

Family

ID=17998727

Family Applications (1)

Application Number Title Priority Date Filing Date
JP30990395A Expired - Fee Related JP3534921B2 (en) 1995-11-02 1995-11-02 Epidermal keratinization promoter

Country Status (1)

Country Link
JP (1) JP3534921B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001213734A (en) * 2000-01-31 2001-08-07 Kanebo Ltd Cosmetics for hair
WO2002030431A1 (en) * 2000-10-12 2002-04-18 Ozeki Corporation Obesity regulatory compositions
JP2011195519A (en) * 2010-03-19 2011-10-06 Maruzen Pharmaceut Co Ltd Melanin production inhibitor, glutathione production promoter, hyaluronic acid production promoter and involucrin production promoter, and skin cosmetic

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001213734A (en) * 2000-01-31 2001-08-07 Kanebo Ltd Cosmetics for hair
WO2002030431A1 (en) * 2000-10-12 2002-04-18 Ozeki Corporation Obesity regulatory compositions
JP2011195519A (en) * 2010-03-19 2011-10-06 Maruzen Pharmaceut Co Ltd Melanin production inhibitor, glutathione production promoter, hyaluronic acid production promoter and involucrin production promoter, and skin cosmetic

Also Published As

Publication number Publication date
JP3534921B2 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
JP4563521B2 (en) Collagen production promoter and topical skin preparation
JPH0585924A (en) External preparation of skin
JP4117773B2 (en) Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one antifungal agent or at least one antibacterial agent
JPH05262635A (en) Dermatic external preparation
JP3534921B2 (en) Epidermal keratinization promoter
JPS5976007A (en) Cosmetic
US6936266B2 (en) Desquamation/epidermal renewal of the skin and/or combating skin aging
JP2000229835A (en) Cosmetic material for improving dullness
JP2001122733A (en) Catalase production-promoting preparation and skin preparation for external use containing the same
JP4056570B2 (en) Lemongrass extract-containing cosmetic
JPH10212225A (en) Wrinkle preventive
JP2001139436A (en) Hair tonic and grower
JPH03112912A (en) Cosmetic composition
JP3083105B2 (en) Cosmetics
JPH0296581A (en) Biotin ester and skin ointment and hair tonic using the ester
EP0740930A1 (en) Blood flow improver and cosmetic
EP3888625A1 (en) Composition for scalp and hair
JP3277033B2 (en) Cosmetics
JPH09263529A (en) Epidermal cornification accelerator
JPS617206A (en) Cell activator
KR20130016929A (en) The cosmetic composition for pore-minimizing and inhibition of sebum secretion containing the extract of leaves of mentha arvensis var. piperascens, wheat bud, and platycodon grandiflorum
JP3222897B2 (en) Cleaning fee
JPH1017440A (en) Hair growing and restoring agent
JP2000178128A (en) Cosmetic for skin and mind
JPH10316575A (en) Epidermis keratinization-promoting agent

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040309

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040310

R150 Certificate of patent (=grant) or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080319

Year of fee payment: 4

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090319

Year of fee payment: 5

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090319

Year of fee payment: 5

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100319

Year of fee payment: 6

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100319

Year of fee payment: 6

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110319

Year of fee payment: 7

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110319

Year of fee payment: 7

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120319

Year of fee payment: 8

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120319

Year of fee payment: 8

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130319

Year of fee payment: 9

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130319

Year of fee payment: 9

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140319

Year of fee payment: 10

LAPS Cancellation because of no payment of annual fees